Physicochemical Properties
| Molecular Formula | C52H72N8O8 |
| Molecular Weight | 937.18 |
| Exact Mass | 936.547 |
| CAS # | 286936-40-1 |
| PubChem CID | 11953346 |
| Appearance | White to off-white solid powder |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 1143.4±65.0 °C at 760 mmHg |
| Flash Point | 645.3±34.3 °C |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.569 |
| LogP | 4.14 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 24 |
| Heavy Atom Count | 68 |
| Complexity | 1250 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | CQVAQQNDZCZBSU-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C52H72N8O8/c1-57(2)25-21-53-45(61)33-65-49-37-13-9-14-38(49)30-40-16-11-18-42(51(40)67-35-47(63)55-23-27-59(5)6)32-44-20-12-19-43(52(44)68-36-48(64)56-24-28-60(7)8)31-41-17-10-15-39(29-37)50(41)66-34-46(62)54-22-26-58(3)4/h9-20H,21-36H2,1-8H3,(H,53,61)(H,54,62)(H,55,63)(H,56,64) |
| Chemical Name | N-[2-(dimethylamino)ethyl]-2-[[26,27,28-tris[2-[2-(dimethylamino)ethylamino]-2-oxoethoxy]-25-pentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(25),3(28),4,6,9(27),10,12,15,17,19(26),21,23-dodecaenyl]oxy]acetamide |
| Synonyms | OTX008; OTX 008; OTX-008 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | OTX008's growth inhibitory concentration (GI50) spans from 3 to 500 μM in a variety of human solid tumor cell lines. In the mold group, there was a strong association found between the levels of protein expression and Gal1 mRNA (LGALS1) and OTX008 GI50 values. OTX008 stimulates G2/M cell cycle signaling through CDK1 and suppresses Gal1 expression as well as ERK1/2- and AKT-dependent survival pathways in SQ20B and A2780-1A9 cells. OTX008 inhibits head formation brought on by exogenous Gal1 and strengthens the anti-apoptotic action of semaphorin-3A (Sema3A) in SQ20B cells [1]. OTX008 has an impact on the shortest, motility, proliferation, and umbilical cord of endothelial cells. Additionally, variations in gravity between cell lines (IC50: 1-190 μM) prevent tumor growth [2]. |
| ln Vivo | The growth of subcutaneously transplanted A2780-1A9 tumors is transcribed by OTX008. OTX008 decreases blood vessel density and transcriptionally controls the expression of Gal1, Ki67, and VEGFR2. When OTX008 was initially introduced, it showed promise in terms of jump treatment and cell multiple toxicity [1]. |
| References |
[1]. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis. Eur J Cancer. 2014 Sep;50(14):2463-77. [2]. Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemother Pharmacol. 2013 Oct;72(4):879-87. |
| Additional Infomation |
OTX008 has been used in trials studying the treatment of Solid Tumors. Galectin-1 Inhibitor OTX008 is a calixarene-based compound and galectin-1 (Gal-1) inhibitor with potential anti-angiogenic and antineoplastic activities. Upon subcutaneous administration, galectin-1 inhibitor OTX008 binds Gal-1 which leads to Gal-1 oxidation and proteasomal degradation, through an as of yet not fully elucidated mechanism, and eventually downregulation of Gal-1. This decreases tumor cell growth and inhibits angiogenesis. Gal-1, a multifunctional carbohydrate-binding protein, is often overexpressed on tumor cells and plays a key role in cancer cell proliferation, apoptosis, tumor angiogenesis and evasion of immune responses. |
Solubility Data
| Solubility (In Vitro) |
Ethanol : ~33.33 mg/mL (~35.56 mM) DMSO : ~5 mg/mL (~5.34 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (1.33 mM) (saturation unknown) in 10% EtOH + 90% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (0.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 3: ≥ 0.5 mg/mL (0.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 4: ≥ 0.5 mg/mL (0.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 5: 0.5 mg/mL (0.53 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0670 mL | 5.3352 mL | 10.6703 mL | |
| 5 mM | 0.2134 mL | 1.0670 mL | 2.1341 mL | |
| 10 mM | 0.1067 mL | 0.5335 mL | 1.0670 mL |